Literature DB >> 17942153

Resistance to Imatinib Mesylate-induced apoptosis in acute lymphoblastic leukemia is associated with PTEN down-regulation due to promoter hypermethylation.

Cristina Montiel-Duarte1, Lucia Cordeu, Xabier Agirre, José Román-Gómez, Antonio Jiménez-Velasco, Edurne San José-Eneriz, Leire Gárate, Enrique J Andreu, Maria José Calasanz, Anabel Heiniger, Antonio Torres, Felipe Prósper.   

Abstract

The aim of our study was to determine the potential mechanism(s) implicated in Imatinib resistance in patients with Ph+ ALL. Resistance of Ph+ ALL cells to Imatinib-induced apoptosis was associated with lack of inhibition of Akt phosphorylation. Addition of the PI3K inhibitor LY294002 to Imatinib significantly increased apoptosis of Ph+ ALL cells. Interestingly, expression of PTEN was reduced in Ph+ ALL cells which was due to PTEN promoter hypermethylation. Treatment of Ph+ ALL cells with 5-Aza-2'-deoxycytidine was associated with an increased expression of PTEN and an increase in cell apoptosis. These results suggest that Imatinib resistance in patients with ALL may be dependent at least in part to PTEN down-regulation due to the abnormal promoter hypermethylation and support the potential role of de-methylating agents for the treatment of patients with Ph+ ALL.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17942153     DOI: 10.1016/j.leukres.2007.09.005

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  15 in total

1.  Phosphorylation of the transcription factor YY1 by CK2α prevents cleavage by caspase 7 during apoptosis.

Authors:  Sarah Riman; Raed Rizkallah; Ari Kassardjian; Karen E Alexander; Bernhard Lüscher; Myra M Hurt
Journal:  Mol Cell Biol       Date:  2011-12-19       Impact factor: 4.272

2.  PTEN over-expression by resveratrol in acute lymphoblastic leukemia cells along with suppression of AKT/PKB and ERK1/2 in genotoxic stress.

Authors:  Arman Ghorbani; Hamid Zand; Mahmood Jeddi-Tehrani; Fariba Koohdani; Farzad Shidfar; Seyed Ali Keshavarz
Journal:  J Nat Med       Date:  2015-05-01       Impact factor: 2.343

3.  ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy.

Authors:  Clara I Aceves-Luquero; Anupriya Agarwal; Juan L Callejas-Valera; Laura Arias-González; Azucena Esparís-Ogando; Luis del Peso Ovalle; Itxaso Bellón-Echeverria; Miguel A de la Cruz-Morcillo; Eva M Galán Moya; Inmaculada Moreno Gimeno; Juan C Gómez; Michael W Deininger; Atanasio Pandiella; Ricardo Sánchez Prieto
Journal:  PLoS One       Date:  2009-07-01       Impact factor: 3.240

4.  In vitro differential sensitivity of melanomas to phenothiazines is based on the presence of codon 600 BRAF mutation.

Authors:  Ogechi N Ikediobi; Mark Reimers; Steffen Durinck; Paul E Blower; Andrew P Futreal; Michael R Stratton; John N Weinstein
Journal:  Mol Cancer Ther       Date:  2008-06-04       Impact factor: 6.261

5.  miR-26a and miR-214 down-regulate expression of the PTEN gene in chronic lymphocytic leukemia, but not PTEN mutation or promoter methylation.

Authors:  Zhi-Jian Zou; Lei Fan; Li Wang; Ji Xu; Run Zhang; Tian Tian; Jian-Yong Li; Wei Xu
Journal:  Oncotarget       Date:  2015-01-20

6.  Identification and comparison of aberrant key regulatory networks in breast, colon, liver, lung, and stomach cancers through methylome database analysis.

Authors:  Byungtak Kim; Seongeun Kang; Gookjoo Jeong; Sung-Bin Park; Sun Jung Kim
Journal:  PLoS One       Date:  2014-05-19       Impact factor: 3.240

7.  Efficacy of dual PI-3K and mTOR inhibitors in vitro and in vivo in acute lymphoblastic leukemia.

Authors:  Jacky Wong; Robert Welschinger; John Hewson; Kenneth F Bradstock; Linda J Bendall
Journal:  Oncotarget       Date:  2014-11-15

8.  PTEN and rapamycin inhibiting the growth of K562 cells through regulating mTOR signaling pathway.

Authors:  Zhi Y Cheng; Xiao L Guo; Xiao Y Yang; Zhi Y Niu; Shi H Li; Su Y Wang; Hao Chen; Ling Pan
Journal:  J Exp Clin Cancer Res       Date:  2008-12-30

9.  Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.

Authors:  Susanne Badura; Tamara Tesanovic; Heike Pfeifer; Sylvia Wystub; Bart A Nijmeijer; Marcus Liebermann; J H Frederik Falkenburg; Martin Ruthardt; Oliver G Ottmann
Journal:  PLoS One       Date:  2013-11-14       Impact factor: 3.240

10.  Methylation analysis of the phosphates and tensin homologue on chromosome 10 gene (PTEN) in multiple myeloma.

Authors:  Giovanna Piras; Maria Monne; Angelo D Palmas; Anna Calvisi; Rosanna Asproni; Francesco Vacca; Laura Pilo; Attilio Gabbas; Giancarlo Latte
Journal:  Clin Epigenetics       Date:  2014-08-20       Impact factor: 6.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.